Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Annual Meeting of Stockholders
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
  • Our Team
    • Leadership Team
    • Board of Directors
  • Publications
  • Scientific Advisory Board
  • Newsroom
  • Investors
  • Contact
Latest News

Publications

  • All
  • COVID-19
  • HIV
  • Oncology
  • GvHD
Infectious Diseases Society of America: Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab

Infectious Diseases Society of America: Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab

Oct 20, 2020
COVID-19
National Library of Medicine: PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry null Mice

National Library of Medicine: PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry null Mice

Feb 24, 2018
GvHD
Antimicrobial Agents and Chemotherapy: Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

Antimicrobial Agents and Chemotherapy: Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

Jul 20, 2010
HIV
RSS
  • « Previous
  • 1
  • 2
© 2023 CytoDyn Inc. All Rights Reserved.
  • Twitter
  • Facebookj
Privacy Policy Disclaimer Sitemap